Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASi-HF Reduced
2024-519525-38-00Phase 3Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Vicadrostat + empagliflozin with Placebo + empagliflozin (2 arms). Primary endpoint: Composite of cardiovascular death, heart failure hospitalization, or urgent heart failure visit. Planned start Aug 2025; status: authorised.
02
Drugs
vicadrostatempagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2024-519525-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519525-38-00.